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Abbreviations:  
APC, antigen-presenting cell 
ASC, antibody-secreting cell 
BMDC, bone marrow-derived dendritic cell 
CpG, cytosine guanine dinucleotide-containing unmethylated DNA motif (in this study: ODN 
1668) 
CTRL, control oligonucleotide (in this study: ODN 1720) 
GM-CSF, granulocyte-macrophage colony-stimulating factor 
IFA, incomplete Freund’s adjuvant; 
INH, TLR9 antagonist oligonucleotide (in this study: ODN 2088) 
LN, lymph node 
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MycHH, a peptide construct consisting of a Myc tag and a HexaHistidine tag, that is 
biotinylated on the N terminus;  
ODN, oligodeoxynucleotide;  
PS, phosphorothioate 
RFI, relative fluorescence intensity 
RU, relative unit 
SA, streptavidin 
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CpG oligodeoxynucleotides (CpG) are widely studied as promising adjuvants in vaccines 
against a range of diseases including infection, cancer or allergy. Conjugating antigen to CpG 
has been shown to potentiate the adjuvant effect via enhancing antigen uptake and danger 
signaling by the very same cell. In the present study, using biotinylated CpG and streptavidin 
as a model system, we demonstrate that CpG motif containing free and antigen-conjugated 
oligonucleotides do not compete in terms of cell activation via TLR9, but do compete for 
cellular uptake. Antigen-conjugated CpG enhances cellular association and uptake of the 
antigen by antigen-presenting cells (APC) and T cells. Free CpG efficiently competes with 
antigen-CpG conjugates in BMDC and T cells, but shows weak or no competition in B cells 
that have higher TLR9 expression. Vaccination with antigen-conjugated CpG or with a 
mixture of antigen and CpG elevates the level of antigen-specific antibodies but co-
administration of CpG-antigen conjugates and free CpG adversely effects immunogenicity. 
These observations may help optimize CpG-based vaccine formulation. 
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Designing vaccines against infectious diseases, allergy or cancer with adjuvants is a central 
issue nowadays. The route of administration, the formulation and the type of the adjuvant can 
fundamentally determine the outcome of the immune response. 
CpG motifs interact with TLR9 in the endolysosomal compartment from which host DNA is 
usually excluded and this ligand binding occurs at a particular stage of endosome maturation 
and acidification [1]. Interaction of TLR9 and  its ligand stimulates an innate immune 
response characterized by the production of cytokines, chemokines and immunoglobulins by 
lymphocytes, macrophages, NK cells and DC [2-4]. In particular, the increased production of 
IL-12 promotes IFN-γ production by NK cells and T cells, and enhances the antigen-specific 
T cell proliferation and differentiation of naïve T cells towards the Th1 phenotype [5]. Most 
of the researchers have focused on the cellular activating effect of the signal transduction 
events that are triggered by TLR9 ligation while less is known about the modulation of 
antigen uptake by CpG ODN. Some authors mentioned the relevance of ’stickiness’ of 
synthetic ODNs [6,7] that can take part in the uptake of antigen and thus have an impact on 
the elicited immune response. There is evidence that ligation of CpG to a particulate antigen 
can enhance the uptake of CpG via endocytosis initiated by the antigen-specific BCR [8]. 
However, when a non-specific B cell or other APC encounters a CpG-antigen conjugate – 
which is probably a more common event in a physiological situation – has not been studied 
widely. Only indirect effects of CpG treatment on enhancement of microbe uptake by 
macrophages [9] or of amyloid β 1-42 peptide by microglial cells [10] were reported. 
We have developed a modular system for experimental vaccination based on streptavidin 
(SA) as a model antigen and monobiotinylated targeting units.  Previously we used 
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enzymatically biotinylated single-chain Ab fragments and studied the effect of vaccination by 
targeting model antigens to various receptors on murine APC, such as CR1/2, FcγRII/III or 
CD40 [
78 
79 
80 
81 
82 
83 
84 
85 
86 
11-13]. Here we describe the effects of targeting our model antigen, SA, to TLR9 
using synthetic CpG oligonucleotide ligands. Unmethylated bacterial DNA fragments, 
containing CpG motifs are the ligands of the pattern recognition receptor TLR9, and these 
ligands are widely investigated as potential molecular adjuvants.  In this paper we report 
competition studies on CpG-mediated antigen uptake and immune response modulation, 
which strengthen the view that CpG-conjugated antigen is taken up preferentially in a 
receptor-mediated fashion.
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2.1.  Ethics Statement 
 
All the treatments of animals (mice) in this research followed the guidelines of the 
Institutional Animal Care and Ethics Committee at Eötvös Loránd University that operated in 
accordance with permissions 22.1/828/003/2007 issued by the Central Agricultural Office, 
Hungary and all animal work was approved by the appropriate committee. 
 
2.2. Animals and cell culturing 
 
Six week old female BALB/c mice were purchased from Charles River Laboratories and were 
housed under specific pathogen free conditions. Cells were cultured in medium RPMI 1640 
(GIBCO - Invitrogen, Carlsbad, CA, US) supplemented with 5% heat-inactivated FCS 
(GIBCO) in the case of spleen cells and supplemented with 10% heat-inactivated FCS in the 
case of BMDC, 2 mM L-glutamine (Sigma–Aldrich, St. Louis, MO, US), 100 U/ml penicillin 
(Sigma–Aldrich), 100 µg/ml streptomycin (Sigma–Aldrich), 50 µM 2-mercaptoethanol 
(Sigma–Aldrich) and 1 mM sodium pyruvate (Reanal, Budapest, HU). 
 
2.3. CpG oligonucleotides 
 
All ODN had phosphorothioate (PS) linkages between the nucleic bases (marked with capital 
letters), except between the last two 3’ bases (marked with lowercase letters). ODN 1668 
(CpG) (TCCATGACGTTCCTGATGCt) and biotinylated 1668 
(TCCATGACGTTCCTGATGCt-biotin) ODN were purchased from Sigma-Aldrich; ODN 
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1720 (CTRL) (TCCATGAGCTTCCTGATGCt), biotinylated 1720 
(TCCATGAGCTTCCTGATGCt-biotin), ODN 2088 (INH) (TCCTGGCGGGGAAGt) and 
biotinylated 2088 (TCCTGGCGGGGAAGt-biotin) were obtained from Kromat Kft 
(Budapest, HU). The PS backbone prevents ODN degradation. 
 
2.4. Generation of bone marrow-derived dendritic cells (BMDC) 
 
The principle method for generating BMDC with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) was adapted from a previous publication [14] with the following 
modifications. BM was flushed from the femurs of BALB/c mice using a 21-gauge needle and 
glucose–potassium–sodium (GKN) buffer. After Tris-ammonium chloride lysis of RBC, BM 
cells were cultured in teflon bottles for 6 days at 37°C in 5% CO2 humidified atmosphere at 
106 cells/ml in complete RPMI 1640 medium, supplemented with GM-CSF.  Recombinant 
murine GM-CSF concentration was adjusted to 34 ng/ml, based on ELISA (BD Biosciences, 
Franklin Lakes, NJ, US) measurement of the supernatant of a murine GM-CSF producing 
X63 mouse myeloma cell line (the kind gift of Zsuzsa Bajtay, ELTE, Budapest, HU). 
According to the results of Zs. Bajtay, the usage of teflon bottles enhances the purity of the 
BMDC culture from 80% to about 92% (unpublished data). The expanded BM culture was 
incubated for one additional day without GM-CSF prior to further in vitro tests. 
 
2.5. In vitro cell activation 
 
Differentiated BMDC culture and freshly isolated spleen cells were plated onto 96 well plates 
in 2×105 and 106 cells/well densities, respectively. Suboptimal activating doses of biotinylated 
or free CpG were used (25 nM for spleen suspension and 50 nM for BMDC culture) with 
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equimolar amount of fluorescent SA (SA-Alexa Fluor 488, Invitrogen) and cells were 
incubated for 1 day (spleen cells) or 2 days (BMDC culture) at 37°C in 5% CO2 humidified 
atmosphere. 
 
2.6. Flow cytometry 
 
Fluorescently labeled mAbs obtained from eBioscience (San Diego, CA, US) were the 
following: anti-mouse CD45R-PerCP-Cy5.5 (clone: RA3-6B2), rat IgG2a-PerCP-Cy5.5 
isotype control (clone: eBR2a), anti-mouse CD69-PE (clone: H1.2F3), armenian hamster IgG-
PE isotype control (clone: eBio299Arm), anti-mouse CD40-APC (clone: 1C10), rat IgG2a-
APC isotype control (clone: eBR2a); Rockland Immunochemicals (Gilbertsville, PA, US): 
polyclonal IgG fraction of anti-Streptavidin (Rabbit); BD Biosciences (Franklin Lakes, New 
Jersey, US): rat anti-mouse I-A/I-E-PE (clone: M5/114.15.2), rat IgG2b, κ-PE isotype control. 
Fluorescently labeled SA was purchased from Invitrogen (Carlsbad, CA, US). For cell surface 
staining, cell suspensions were incubated on ice for 20 min with different combinations of 
mAb, diluted in FACS buffer (PBS supplemented with 1% heat-inactivated FCS and 0.1% 
sodium azide). Nonspecific binding was blocked using K9.361 Ab (ELTE, Department of 
Immunology, Budapest, HU). After staining with fluorescently labeled mAb, cells were 
washed and acquired by a FACSCalibur (BD Biosciences) flow cytometer and the results 
were analyzed using FCSExpress (De Novo Software). In the spleen cell suspension CD45R+ 
lymphocyte-sized cells were considered B cells and CD45R- lymphocyte-sized cells were 
considered T cells. In the BMDC suspension I-A/I-E+ cells were considered BMDC. Dead 
cells were excluded on the basis of their light scattering properties. Anti-SA antibody was 
used to detect cell-surface associated SA, whereas SA-fluorescence itself could be originated 
from both the internal compartments of the cells and from the cell surface. Results of flow 
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cytometry (Fig. 2, Fig. 3 and SuppFig. 1) were expressed as relative fluorescence intensities 162 
(RFI), which were calculated as follows. The geometric mean of fluorescence of  a particular 163 
cell population acquired after a given treatment was divided by the the geometric mean of 164 
fluorescence acquired from the SA-treated control sample. RFI = MFI(any treatment) / MFI(SA 165 
treatment). Results of at least three independent experiments were summarized on the diagrams 166 
of Fig. 2, Fig. 3 and SuppFig. 1. 167 
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2.7. Immunization protocol 
 
The vaccine formulation contained equimolar complexes of 5 µg (83.3 pmol) Streptavidin 
(SA) (Sigma–Aldrich) and biotinylated synthetic, N-terminally biotinylated myc-his-tag 
peptide (MycHH, sequence: biotin-SSSAAAEQKLISEE-DLNHHHHHH) (Sigma–Aldrich). 
The SA-MycHH complex served as a model antigen in the immunizations. Biotinylated 
and/or free CpG, CTRL or INH ODN were added to the SA-MycHH complex in equimolar 
amounts.  
For in vivo experiments, 8 female BALB/c mice per group (6-8 week old) were injected s.c. 
into the hind footpads and the base of the tail with the treatments containing 5 µg SA/mouse, 
mixed with equal volume of Incomplete Freund’s adjuvant (IFA; Sigma-Aldrich) in a total 
volume of 150 µl/animal (Table 1, Fig. 1). A booster injection with the same concentration 
and volume of adequate complexes was administered in IFA on day 14. Blood samples were 
taken on day 0, 7, 21 and 28. Mice were sacrificed on day 28 and cells were isolated and 
purified from the inguinal and popliteal lymph nodes (LN). 
 
2.8. ELISA 
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Levels of antigen specific IgG1 and IgG2a were determined as described previously [12]. 
Briefly, 96-well plates were coated first with SA (Sigma–Aldrich) and then with biotinylated 
MycHH peptide (Sigma–Aldrich). Following blocking, serial dilutions of sera of immunized 
mice were measured into the wells in triplicates. Goat anti-mouse IgG1-HRP or goat anti-
mouse IgG2a-HRP (Southern Biotech, Birmingham, AL, USA) was used for detecting 
antigen-specific antibodies. Relative concentrations were calculated using monoclonal mouse 
anti-Myc-tag IgG1 (clone 9E10, Cell Signaling Technology, Danvers, MA, US) and mouse 
anti-Myc-tag IgG2a (clone 9B11, Cell Signaling Technology) as standards. Results are 
represented as relative units (RU). 
 
2.9. Reverse ELISPOT assay 
 
The number of antibody-secreting cells (ASC) in the draining LN after immunizations was 
determined as described previously [13]. Briefly, 5×105 cells, isolated from draining LN of 
immunized mice were incubated in quadruplicates for 20 h at 37ºC. Plates were then washed 
and incubated with SA-HRP (Sigma-Aldrich) conjugated to MycHH in equimolar amounts 
(1.67 nM) at 37ºC for 1 h. The spots were developed, the membranes were washed, dried and 
scanned, and the number of spots was determined by the ImmunoSpot software (C.T.L.). 
 
2.10. Reverse Protein Microarray 
 
Sera from all immunized mice were spotted individually onto nitrocellulose-covered glass 
slides using a BioOdyssey Calligrapher miniarrayer (Bio-Rad Laboratories, Hercules, CA, 
US). Features were printed in triplicates of 1:5 dilutions then stored at 4 °C in sealed bags. 
Dried arrays were rinsed in PBS for 15 min before use, and then blocked with PBS containing 
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5% BSA (Sigma-Aldrich) and 0.05% Tween 20 (BSA-PBS-Tween) for 30 min at RT. 
Antigen complexes was prepared by conjugating SA-Alexa647 (Molecular Probes, 
Invitrogen) to biotinylated MycHH peptide (Sigma–Aldrich) in 1:1 molar ratio and diluted 
1:4000 in BSA-PBS-Tween. Labeling with the antigen (SA-MycHH complex) was conducted 
at room temperature for 1 h in BSA-PBS-Tween. Following washing in PBS-Tween, arrays 
were dried and scanned with an Axon GenePix 4300A scanner and data were analyzed with 
GenePixPro 7 software (Molecular Devices). Relative fluorescence intensities (RFI) were 
calculated by subtracting background fluorescence from the median of three parallel signal 
intensities. Signals not exceeding two standard deviations of local background signals on a 
slide were clamped to an arbitrary value of 1. 
  
2.11. MACS 
 
For gene expression studies differentiated BMDC were positively separated from the BM 
culture with anti-mouse CD11c magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, 
DE) according to the manufacturer’s protocols. FcRs were blocked by naive BALB/c serum. 
Activated spleen suspension was separated to CD19+ (B cell) and CD19- (T cell) populations 
with anti-mouse CD19 magnetic beads (Miltenyi Biotec). The purity of the resulting B and T 
cell suspensions was at least 95%. 
 
2.12. Analysis of TLR9 gene expression by qPCR 
RNA was extracted from magnetically separated CD19 positive B cells, CD19 negative T 
cells and CD11c positive BMDC using TRIzol reagent (Life Technologies, Carlsbad, CA, 
US) and converted to cDNA for real-time PCR analysis as described previously [15]. Real-
time PCR was performed on an ABI PRISM 7000 Sequence Detection System (Applied 
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Biosystems). TLR9 mRNA was quantified using primers and FAM-labeled probes from 
Applied Biosystems (Taqman assays on demand) according to the manufacturer’s 
instructions. Variations in cDNA input were normalized using β2m (Applied Biosystems) as a 
reference gene and the expression level of TLR9 in B and T cells was calculated as the n-fold 
difference relative to the expression found in BMDC. 
 
2.13. Statistical analysis 
Regarding in vitro experiments, all data were normalized to the data of SA treatment and 
statistical differences were assessed by pairwise comparisons of relevant groups using 
permutation tests with the help of the software R. Briefly, values from the groups to be 
compared were randomly reassigned to two groups and the difference between the group 
means was calculated. Distribution of 5000 randomizations was drawn and the two-tailed p 
value corresponding to the real sample assignments was determined. The arithmetic mean of 
50 such p values was accepted as the probability of α-error.  Values of p < 0.05 were 
considered significant and were indicated as follows: *p < 0.05; **p < 0.01; ***p < 0.001. 
Statistical differences between the control and the experimental immunization groups were 
determined by nonparametric, Kruskal-Wallis ANOVA analysis for ELISA and ELISPOT 
and reverse protein array experiments, using Statistica 8 software (StatSoft). Quantitative data 
are expressed as individual data of mice; the horizontal lines indicate medians of the groups. 
Levels of significance were indicated with asterisks as mentioned previously.  
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3.1. Antigen-conjugated CpG enhances cellular association and uptake of the antigen by 
APC and T cells 
 
We characterized the efficiency of antigen capture and uptake using fluorescently labeled SA. 
Synthetic biotinylated CpG (ODN 1668) was mixed with SA in a 1:1 ratio and coincubated 
with bone marrow-derived dendritic cells (BMDC), and splenocyte suspension. B220 positive 
splenocytes were referred to as B cells, and B220 negative splenocytes were referred to as T 
cells. Conjugating CpG to the protein antigen resulted in enhanced association to B and T 
lymphocytes and BMDC after 24 h of incubation (Fig. 2). To exclude that increased 
fluorescence was a result of SA-CpG sticking to the cell surface, SA accessibility was 
assessed by anti-SA antibodies. Weak or missing anti-SA signals indicated that cellular 
uptake was mainly responsible for CpG-mediated SA association to the cells (Fig. 2). The 
level of APC activation was low because the doses of CpG used here were titrated to be 
suboptimal to allow modulation in the following competition studies. There was no difference 
between the activatory potential of SA + CpG and SA-CpG treatments (Fig. 2).  
 
3.2. Non-biotinylated excess CpG efficiently competes with CpG-antigen conjugates on 
BMDC and T cells, but shows weak or no competition on B cells  
 
In order to prove that the increase in uptake of SA-CpG complexes compared to the uptake of 
SA alone is due to a receptor-mediated and therefore a saturable process we tested the effects 
of free CpG and other types of ODN on the SA-CpG uptake. In the presence of a 100-fold 
molar excess of free CpG, association of SA-CpG complexes to T cells and BMDC was 
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robustly reduced. In contrast, the SA-CpG uptake of B lymphocytes could not be inhibited 
even with a 100-fold excess of free CpG (Fig. 3A).  
Although the addition of excess CpG resulted in enhanced B cell and BMDC activation, the 
difference between association of SA-CpG to the different cell types was not a consequence 
of the strong activation of B cells, since the same results were observed with excess CTRL 
(ODN 1720) that has little or no activating effect (Fig. 3B). A TLR9 inhibitor ODN, marked 
INH (ODN 2088) showed competition with SA-CpG in the case of all three cell types though 
with less efficiency (Fig. 3C). The addition of excess ODN had no effect on SA accessibility 
on the cell surface (Supplementary Fig. 1A–C), except in the case of B cells treated with SA-
CpG + INH in 100-fold excess. In this last case the inhibitory ODN also competed with the 
low amounts of cell surface bound SA-CpG complexes (Supplementary Fig. 1C). 
As the weak competition between free and antigen-conjugated CpG in B cells could not be 
explained by the activatory effect of excess CpG, we performed RT-PCR measurements to 
compare the expression of TLR9 in these cell types. Both in untreated and activated B cells, 
the expression of TLR9 was much higher compared to BMDC or T cells (Supplementary Fig. 
2A-B), suggesting that saturation of the receptor would be more difficult to achieve in these 
cells. 
 
3.3. CpG conjugation to SA elevates the level of antigen-specific antibodies 
 
As we found that CpG facilitates the accumulation of a CpG-conjugated protein in DC and 
this can be inhibited by free CpG, the question arose, whether this phenomenon would occur 
in vivo. To test this hypothesis we vaccinated mice with four different formulations of a SA-
peptide complex with CpG or other ODN. The biotinylated c-myc-HexaHistidine tag peptide 
(MycHH) that was conjugated to SA in equimolar ratio served as a positive control epitope 
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during serological detection. The peptide content is not indicated separately to simplify the 
nomination of the vaccine formulations that are summarized in Table 1 and Fig. 1. SA was 
administered in itself (SA), together with non-biotinylated free CpG (SA + CpG); together 
with biotinylated CpG to form complexes (SA-CpG) and together with a 1:1 mixture of 
nonbiotinylated and biotinylated CpG (SA-CpG + CpG). For the last group the amount of free 
and biotinylated CpG together was equal to the CpG amount of the other groups. IFA was 
used to ensure the development of an immune response since relatively low amount of CpG 
was used (83 pmol/mice/injection). We used suboptimal CpG doses to be able to modulate the 
immune response and in order to avoid systemic responses caused by high-dose soluble CpG.  
First, we compared the effect of the conjugation of biotinylated forms of the different ODN 
used in the in vitro experiments (CpG, CTRL or INH) to the model antigen SA. Conjugation 
of antigen to CpG, but not to the other two types of ODN, elevated the level of antigen-
specific antibodies (Fig. 4A). At this dosage only conjugated but not free CpG had 
statistically significant immune response enhancing effect, as shown by reverse array (Fig. 
4B), ELISA (Fig. 5A-B) and ELISPOT (Fig. 6). 
 
3.4. Free CpG adversely influences the adjuvant effect of antigen-CpG conjugation 
 
To study the in vivo interactions between free CpG and SA-CpG complexes, we prepared a 
formulation where half of the CpG was conjugated to SA, and half of it was in free form. 
Interestingly, instead of showing an additive effect, vaccination with the SA-CpG + CpG 
formulation did not enhance immune responses at all (Fig. 4B - Fig. 6). Antigen-specific Ab 
levels (Fig. 4B, 5B) and the number of Ab secreting cells (Fig. 6) were comparable to the SA 
group where no CpG was present, and were significantly lower compared to the SA-CpG 
group.  
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TLR9 is recognized as the primary receptor for unmethylated bacterial CpG DNA, which 
triggers signaling and gene transcription upon binding to TLR9 in the endosomes. Here we 
showed that a protein antigen efficiently accumulates in different leukocytes when it is linked 
to a TLR9 ligand, a single-stranded phosphorothioate-protected (PS) CpG ODN. The 
mechanism of CpG uptake is controversial, as non-specific internalization [16] as well as 
specific uptake mechanisms have been suggested. Various receptors and transfer molecules 
came into view as potential CpG binders, like CD14 [17],  membrane bound scavenger 
receptors like CXCL16 [18] or SR-A and MARCO [19], DEC-205 [20], human CR2 [21], the 
KIR3DL2 receptor on human NK cells [22], and alpha 2-macroglobulin [23]. It has also been 
proposed that the uptake of ODN that have a PS backbone differs from that of natural 
phosphodiester backboned ODN, and PS ODN bind to many proteins due to nonspecific 
interactions [24]. The number of these - sometimes controversial - studies shows that there is 
much to be done to elucidate the uptake mechanisms of CpG ODN or its synthetic analogues 
and to better understand the intracellular fate and mechanism of effect of complexes that 
consist of protein antigen and CpG. Whatever the internalization mechanism could be, our 
results point to a TLR9-mediated accumulation that can be saturated in cells where TLR9 
expression is low. Of the two APC types we studied, splenic B-cells showed more than ten 
times higher expression of TLR9 compared to BMDC (Supplementary Fig. 2, 
www.immgen.org, 2013). Splenic T cells also express TLR9 at low levels, which delivers 
costimulatory signals for TCR-induced activation [
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25]. About tenfold increase in fluorescence 
signal was observed, when cells were incubated with fluorescent SA conjugated with CpG 
(SA-CpG), compared to the incubation with a SA + CpG mixture. In the case of B cells part 
of the SA-fluorescence originated from the surface of the cells, as SA was detected by anti-
16 
 
SA antibodies (Fig. 2). Thus, the extent of SA-CpG accumulation was not proportional to 
TLR9 expression, indicating that other factors limited maximal accumulation. On the other 
hand, competition experiments were in agreement with TLR9 expression levels: higher 
amounts of free ODN were required to inhibit SA accumulation by B cells. ODN with PS 
backbone have been shown to compete for TLR9 binding [
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26], explaining the competitive 
effect of CTRL and INH (Fig. 3). Taken together these results suggest that TLR9 retains 
CpG-conjugated SA within the cells. 
 
Antigen-conjugated CpG activated APC, such as B cells and DC, but not T cells. These 
results are in line with previous works showing that in contrast to APC that are activated by 
CpG stimulus alone [27], naive T cells need additional TCR ligation to be able to react to 
CpG stimuli, reviewed in [28]. Moreover, Landrigan et. al. showed that this costimulating 
effect of different ODN on T cells occurs independently of TLR9 and MyD88, and TLR9 
antagonists can also promote costimulation of anti-CD3 treated CD4+ T cells [25].  
 
Our immunization studies suggest that instead of showing additive immunostimulatory 
properties, antigen-conjugated and free CpG rather cancel out each other’s effects. Both the 
number of antigen-specific ASC and the circulating Ab levels were comparable to 
immunizations with SA alone, and were significantly weaker than the SA-CpG induced 
effects (Fig. 4-6). We speculate that competition between SA-CpG complexes and free CpG 
occurs in DC in vivo, resulting in poorer antigen uptake or accumulation by these cells.  
The amounts of CpG and antigen we used for immunizations (83.3 pmol/mouse) were set to 
be close to the minimum concentration that was needed to trigger cell activation in vitro (5 
pmol for 106 spleen cells or 10 pmol for 2×105 BMDC). By comparison, in other vaccination 
studies where the aim was to elicit a strong immune response against the injected antigen, 
17 
 
orders of magnitude higher amounts of CpG were used [29-31]. In contrast to these studies, 
the concentration we used might be rather suitable for monitoring subtle differences between 
the immunomodulating effects of immunization with materials of similar composition but 
different formulation. Our purpose was also to avoid systemic reactions known to be induced 
by high amounts of soluble CpG [
382 
383 
384 
385 
386 
387 
388 
389 
390 
391 
392 
393 
394 
32,33]. 
 
In conclusion, beside the direct activating effect of CpG exerted on the target cells via TLR9, 
CpG-coupled antigens also show improved cellular uptake, which could contribute to the 
enhanced immune response against such conjugates. The identity of the receptor responsible 
for improved cellular uptake remains to be confirmed; nevertheless competition between free 
CpG and CpG coupled to antigen reduces the amount of antigen that accumulates in the target 
cells. Thus, surplus free CpG can even hinder rather than promote the effects of CpG-coupled 
antigens when these are used at concentrations relevant for modeling human vaccination.
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Figure 1. Composition of complexes and labeling of cells. 
Composition of complexes used for in vitro treatments and vaccines and the labeling of 
BMDC and spleen cells for in vitro tests. 
 
Figure 2. Comparing the effects of free and antigen-conjugated CpG on antigen uptake 
and cell activation. 
Total SA shows the association of labeled SA to either in- or outside of the cells, surface SA 
shows the anti-SA staining of the complexes only on the cell surface. Activation is measured 
by the detection of activation marker upregulation (CD40 on BMDC and CD69 on spleen cell 
suspension). The concentration of the different treatments was 50 nM for BMDC and 25 nM 
for spleen cells. Cells were harvested 24 h after stimulation and analyzed by flow cytometry. 
CD45R+ lymphocyte-sized cells were considered B cells, CD45R- lymphocyte-sized cells 
were considered T cells, I-A/I-E+ cells were considered BMDC. The diagrams show mean + 
SD of at least three independent experiments, normalized to the SA treatment. Statistical 
differences were assessed by pairwise comparisons of SA + CpG and SA-CpG groups using 
permutation tests, *p < 0.05; ***p < 0.001. RFI, relative fluorescence intensity. 
 
Figure 3. Comparing the effects of different excess ODN on the uptake of SA-CpG and 
cell activation.  
Non-biotinylated CpG (A), CTRL (B) and INH (C) ODN were added in 10- and 100-fold 
excess. Total SA shows the association of labeled SA to either in- or outside of the cells and 
activation is measured by the detection of activation marker upregulation (CD40 on BMDC 
and CD69 on spleen cell suspension). The concentration of SA-CpG was 50 nM for BMDC 
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and 25 nM for spleen cells. Cells were harvested 24 h after stimulation and analyzed by flow 
cytometry. CD45R+ lymphocyte-sized cells were considered B cells, CD45R- lymphocyte-
sized cells were considered T cells, I-A/I-E+ cells were considered BMDC. The diagrams 
show mean + SD of at least three independent experiments, normalized to the SA treatment. 
Statistical differences were assessed by pairwise comparisons of the SA-CpG treatment and 
the treatments containing excess ODN, using permutation tests, *p < 0.05; **p < 0.01; ***p < 
0.001. RFI, relative fluorescence intensity. 
 
Figure 4. Levels of antigen-specific total Ig on day 28 after immunization.  
Eight female BALB/c mice per group were injected s.c. into the hind footpads and the base of 
the tail with equimolar SA complexes containing 5 µg SA/mouse, mixed with equal volume 
of IFA, followed by a booster injection with the same treatments on day 14. Blood samples 
were taken on day 28 and total levels of antigen-specific antibodies were assessed by reverse 
protein microarray. Comparison of antigen-specific Ig levels following vaccination with 
different ODN (CpG, CTRL or INH) conjugated to SA (A). Comparison of antigen-specific 
Ig levels following vaccination with SA-conjugated and/or free CpG (B). Each dot represents 
data obtained from one mouse and horizontal lines show the medians of the groups. Statistical 
significance was calculated using a Kruskal-Wallis test (non parametric 1-way Anova), and a 
Dunn’s post hoc test. *p<0.05 and **p<0.01. RFI, relative fluorescence intensity. 
 
Figure 5. Concentration of antigen-specific IgG1 and IgG2a antibodies on day 28 after 
immunization. 
Eight female BALB/c mice per group were injected s.c. into the hind footpads and the base of 
the tail with equimolar SA complexes containing 5 µg SA/mouse, mixed with equal volume 
of IFA, followed by a booster injection with the same treatments on day 14. Blood samples 
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were taken on day 28 and the levels of antigen-specific IgG1 (A) and IgG2a (B) antibodies 
were measured by ELISA. Each dot represents data obtained from one mouse and horizontal 
lines show the medians of the groups. Statistical significance was calculated using a Kruskal-
Wallis test (non parametric 1-way Anova), and a Dunn’s post hoc test. **p<0.01. Results are 
represented as relative units (RU). 
 
Figure 6. The numbers of antigen-specific ASC in the regional lymph nodes on day 28 
after immunization. 
Eight female BALB/c mice per group were injected s.c. into the hind footpads and the base of 
the tail with equimolar SA complexes containing 5 µg SA/mouse, mixed with equal volume 
of IFA, followed by a booster injection with the same treatments on day 14. Mice were 
sacrificed on day 28 and the number of antigen-specific ASC in the regional LN was assessed 
by reverse ELISPOT. Results are represented as number of antigen-specific ASC/5×105 cells. 
Each dot represents data obtained from one mouse and horizontal lines show the medians of 
the groups. Statistical significance was calculated using a Kruskal-Wallis test (non parametric 
1-way Anova), and a Dunn’s post hoc test. *p<0.05 and **p<0.01. ASC, antibody-secreting 
cell. 
 
Supplementary Figure 1. Comparing the effects of different excess ODN on the cell 
surface SA levels.  
Non-biotinylated CpG (A), CTRL (B) and INH (C) ODN were added in 10- and 100-fold 
excess. Surface SA shows the anti-SA staining of the complexes on the cell surface. The 
concentration of SA-CpG was 50 nM for BMDC and 25 nM for spleen cells. Cells were 
harvested 24 h after stimulation and analyzed by flow cytometry. CD45R+ lymphocyte-sized 
cells were considered B cells, CD45R- lymphocyte-sized cells were considered T cells, I-A/I-
26 
 
E+ cells were considered BMDC. The diagrams show mean + SD of at least four independent 
experiments, normalized to the SA treatments. The treatments containing excess ODN were 
compared to the SA-CpG treatment. Statistical differences were assessed by pairwise 
comparisons of relevant groups using permutation tests, *p<0.05. Anti-SA antibody control 
(D): levels of total and surface SA after labeling spleen B cells with SA on ice, using an anti-
CR1/2 scFv-SA complex. The diagrams show mean + SD of two independent experiments, 
normalized to the SA treatments. No statistical significance was calculated. RFI, relative 
fluorescence intensity. 
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Supplementary Figure 2. Relative mRNA expression of TLR9 in non-activated and 
activated BMDC, B cells and T cells.  
After 24 h of incubation with or without CpG (50 nM CpG for BMDC and 25 nM CpG for 
spleen cells) BMDC were positively separated from BM culture with anti-mouse CD11c 
magnetic microbeads or biotinylated anti-mouse I-A/I-E and anti-biotin magnetic microbeads. 
Spleen suspension was separated to CD19+ (B cell) and CD19- (T cell) populations with anti-
mouse CD19 magnetic beads. RNA was extracted and converted to cDNA for quantitative 
real-time PCR analysis. Variations in cDNA input were normalized using β2m (Applied 
Biosystems) as a reference gene and the expression level of TLR9 in B and T cells was 
calculated as the n-fold difference relative to the expression found in BMDC. Each dot depicts 
technical parallels and horizontal lines indicate their mean. Representative results of three 
independent experiments are shown.  
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Table 1. Name and composition of vaccines. 
Name Composition 
SA  SA-MycHH-biotin (in IFA) 
SA + CpG  SA-MycHH-biotin + CpG (in IFA) 
SA-CpG  SA-MycHH-biotin-CpG-biotin (in IFA) 
SA-CpG + CpG  SA-MycHH-biotin-CpG-biotin + CpG (in IFA) 
SA-CTRL  SA-MycHH-biotin-CTRL-biotin (in IFA) 
SA-INH  SA-MycHH-biotin-INH-biotin (in IFA) 
 
Each treatment contained 5 µg (83.3 pmol) SA/mouse, and all other components in equimolar 
ratios. In the case of SA-CpG + CpG the total amount of ODN was 83.3 pmol. Each treatment 
contained 75 µl IFA/mouse. The prime and the boost vaccine contained the same materials in 
the same amounts. 
SA, streptavidin; 
MycHH, biotinylated Myc-tag HexaHis tag pepide; 
CpG, CpG motif containing ODN 1668; 
CTRL, ODN 1720 that contains the CG basepair of the CpG motif of ODN 1668 in reverse 
order; 
INH, ODN 2088 that binds to but inhibits activation of TLR9; 
IFA, incomplete Freund’s adjuvant. 








